- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
GE’s MR-Touch marks first commercial release of MR elastography
GE Healthcare unveiled at RSNA 2009 a software technique that uses low-frequency sound waves in combination with MRI to measure the elasticity of liver tissue as an indicator of disease.
GE Healthcare unveiled at RSNA 2009 a software technique that uses low-frequency sound waves in combination with MRI to measure the elasticity of liver tissue as an indicator of disease. The technology underlying this new product, called MR-Touch, was developed at the Mayo Clinic in Rochester, MN, and licensed to GE. It extends the principles of physical palpation and MR as a way to evaluate tissue stiffness.
GE is framing MR-Touch as a precise, noninvasive and cost-effective way to detect, monitor, and understand disease. The FDA-cleared technique detects changes in the liver that indicate the presence of disease. It can also be used to monitor disease progression and provide more informed preventive guidance. Perhaps most important, the method supports a comfortable experience for the patient.
MR-Touch will be commercially available as an option to GE's newly released wide-bore 1.5T MR scanner, the Optima MR450w.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
